NCT06434363View on ClinicalTrials.gov

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Autoimmune DisordersSystemic SclerosisSystemic Lupus ErythematosusLupusLupus Nephritis
Interventions
DRUG

Tafasitamab

Given by vein (IV)

DRUG

Fludarabine phosphate

Given by vein (IV)

DRUG

Cyclophosphamide

Given by vein (IV)

DRUG

Tafasitamab and NK cells

Given by vein (IV)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER